Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2019

View Archived Issues

FDA clears IND for NantKwest's CD19.t-haNK cell therapy

GlaxoSmithKline initiates phase I study of HBV therapeutic vaccines

Pfizer initiates phase II study of PF-06700841 topical cream for atopic dermatitis

First-in-human data presented for TAS-119

TVB-2640 in combination with bevacizumab results in promising PFS in patients with recurrent GBM

Phase I data for CC-90010 in patients with advanced solid tumors and non-Hodgkin's lymphoma

Clinical study foreseen for Immunic's autoimmune disease candidate IMU-935

Microbiome metabolism influences drug responses

Novel ruthenium(II) complex induces apoptosis and inhibits angiogenesis in tumor animal models

Rifamycin SV-MMX evaluated in phase II study for acute uncomplicated diverticulitis

Promising results of phase I trial of CAL-02 in severe community-acquired pneumococcal pneumonia

TXNRD1 blockade found to play protective role in acute lung injury

New gene variants found to protect against osteoporosis in patients with Gaucher's disease

Phase III ELEVATE-TN trial of Calquence in previously untreated CLL meets primary endpoint

Asclepius initiates phase I/II study of BCMA CAR-NK cells in relapsed/refractory multiple myeloma

Partial response observed in ongoing phase II study of BN-Brachyury for chordoma

Phase III study of Ninlaro in systemic AL amyloidosis misses first of two primary endpoints

Vaccitech initiates phase IIb study of MVA-NP+M1 universal flu vaccine in Belgium

Concert Pharmaceuticals presents phase I preliminary data for CTP-692

Novartis discovers HBsAg secretion inhibitors

New mGlu2 negative allosteric modulators synthesized at Sumitomo Dainippon Pharma

Senju Pharmaceutical synthesizes new PAC1 and/or VPAC1 and/or VPAC2 receptor ligands

Hepagene Therapeutics patents MEK kinase 5 inhibitors

Metabomed identifies acetyl-coenzyme A synthetase, cytoplasmic inhibitors

InflaRx reports topline results from phase IIb SHINE study of IFX-1 in hidradenitis suppurativa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...